Anavex Life Sciences (AVXL) Q4 2024 earnings summary

Executive summary

• EMA accepted the marketing authorization application for blarcamesine (ANAVEX®2-73) for Alzheimer's disease, supported by phase 2b/3 trial data and a 144-week open-label extension study, with review starting December 23, 2024.

• Top-line long-term data from the ATTENTION-AD open-label extension trial will be presented at the J.P. Morgan 2025 Healthcare Conference.

• Peer-reviewed manuscript on blarcamesine phase 2/3 trial results was accepted for publication, expected within the current or next quarter.

• New data from the phase 2b/3 study confirmed clinical efficacy and mechanism of action for blarcamesine in early Alzheimer's disease.

• Preliminary phase 2 results for ANAVEX®3-71 in schizophrenia showed dose-dependent effects on EEG biomarkers.

Financial highlights

• Cash and cash equivalents at September 30, 2024, were $132.2 million, with no debt and a four-year estimated runway.

• Cash used in operating activities during the quarter was $6.7 million.

• General and administrative expenses were $2.8 million, up from $2.6 million in Q4 2023.

• Research and development expenses were $11.6 million, up from $10.1 million in Q4 2023.

• Net loss for the quarter was $11.6 million, or $0.14 per share.

Outlook and guidance

• Current cash utilization rate provides an estimated runway of four years.

• EMA review process for blarcamesine is expected to take 210 days.

• Data from part B of the ANAVEX®3-71 phase 2 study in schizophrenia expected in the first half of 2025.

• Update on ATTENTION-AD open-label extension study to be presented at J.P. Morgan 2025 Healthcare Conference.